Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Autor: Gokhan Ozyigit, Ali Murat Sedef, Ezgi Oymak, Sadık Muallaoğlu, Ahmet Taner Sümbül, Fatih Kose, Berna Akkus Yildirim, Huseyin Mertsoylu, Ozan Cem Guler, Ali Ayberk Besen, Cem Onal, Sercan Aksoy
Rok vydání: 2019
Předmět:
Male
Survival
medicine.medical_treatment
Abiraterone Acetate
Metastasis
030218 nuclear medicine & medical imaging
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
Prostate
Local recurrence
Aged
80 and over
Abiraterone acetate
Radiotherapy Dosage
Middle Aged
Prognosis
Combined Modality Therapy
Primary tumor
Prostatic Neoplasms
Castration-Resistant
Prostate-specific antigen
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
medicine.medical_specialty
Urology
Antineoplastic Agents
Hormonotherapy
Adenocarcinoma
Castration resistant
Drug Administration Schedule
03 medical and health sciences
Biomarkers
Tumor
medicine
Humans
Radiology
Nuclear Medicine and imaging
Aged
Neoplasm Staging
Retrospective Studies
Lymphatic Irradiation
business.industry
Prostate-Specific Antigen
medicine.disease
Radiation therapy
chemistry
Prednisone
Radiotherapy
Adjuvant
business
Follow-Up Studies
Zdroj: Strahlentherapie und Onkologie. 195:872-881
ISSN: 1439-099X
0179-7158
DOI: 10.1007/s00066-019-01429-6
Popis: Purpose To evaluate the potential benefit of curative radiotherapy (RT) to the primary tumor in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone. Materials and methods The clinical parameters of 106 mCRPC patients treated with abiraterone were retrospectively evaluated. Patients were either oligometastatic (= 50% of the baseline obtained 3 weeks after abiraterone therapy was the only significant prognostic factor for better OS and progression-free survival (PFS). Patients treated with primary RT to the prostate had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT. Conclusions Local prostate RT significantly improved OS and local control in mCRPC patients treated with abiraterone. The patients treated with primary RT had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT.
Databáze: OpenAIRE
Externí odkaz: